Drug Trial Radar · NCT00102479
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jul 1, 2004
Primary completion
Jul 1, 2005
Study completion Jul 1, 2005
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jan 31, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
Conditions
- Schizophrenia
- Mania
Interventions
AripiprazoleDrug
Aripiprazole tablets ranging from 2 to 30 mg to be taken orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Able to Tolerate Maximum Dose LevelTime frame: 14 Days
- Number of Participants With Adverse Events, Serious Adverse Events and Discontinuation Due to Adverse Event as a Measure of SafetyTime frame: 57 days
- Aripiprazole Maximum Steady State Plasma Concentration (Css,Max)Time frame: Pre-dose and 1 to 24 hours post-dose on Day 14
- Aripiprazole Time to Maximum (Peak) Plasma Concentration (Tmax)Time frame: Pre-dose and 1 to 25 hours post-dose on Day 14
- Aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)Time frame: Pre-dose and 1 to 24 hours post-dose on Day 14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.